HAT Activator HDAC Inhibitor Composition for Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases like Alzheimer's and cancers are palliative and lack effective treatments, with existing HAT activators being insoluble and membrane-impermeable, and there is a need for novel HAT activators and treatments for these conditions.
Innovation Solution
A pharmaceutical composition comprising a HAT activator and a HDAC inhibitor is developed, with specific structures and combinations for treating cancer and neurodegenerative diseases, including administering compounds like RP14, RP52, and romidepsin to increase histone and p53 acetylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing HAT activators (CTPB, CTB, Nemorosone) are used, then HAT activity is enhanced, but solubility and membrane permeability are poor
Solution Approach 1:
The patent modifies the chemical structure of HAT activators by changing physical and chemical parameters such as adding solubilizing groups (carboxylic acid, hydroxyl, amino groups) and modifying molecular weight and lipophilicity to improve both solubility and membrane permeability while maintaining HAT activation efficacy
Solution Approach 2:
The invention creates composite molecular structures that combine the core HAT-activating moiety with solubilizing and membrane-permeable moieties, effectively creating a composite material that exhibits multiple desirable properties simultaneously
2Reliability
If HDAC inhibitors are used alone, then histone acetylation is increased, but transcriptional activation and gene expression are insufficient
Solution Approach 1:
The patent combines HAT activators and HDAC inhibitors into a single pharmaceutical composition, creating a synergistic effect where HAT activators directly enhance acetyltransferase activity to produce acetylated histones and activate transcription, while HDAC inhibitors prevent deacetylation, thereby amplifying the overall transcriptional activation and gene expression outcome
Solution Approach 2:
The combination therapy ensures continuous maintenance of hyperacetylated chromatin state by simultaneously promoting acetylation (HAT activation) and preventing deacetylation (HDAC inhibition), creating a sustained transcriptionally active environment that enhances therapeutic efficacy over time
3Ease of operation
If palliative therapies are used for neurodegenerative diseases, then symptom management is provided, but disease progression is not halted
Solution Approach 1:
The patent employs HAT activators and HDAC inhibitors to preliminarily modify the epigenetic state of neurons before significant neurodegeneration occurs, promoting expression of neuroprotective genes and maintaining chromatin in a transcriptionally active state that prevents disease progression rather than merely managing symptoms after damage has occurred
4Reliability
If conventional cancer therapies are used, then tumor growth is controlled, but treatment efficacy is limited and resistance develops
Solution Approach 1:
The patent changes the therapeutic parameter from conventional cytotoxic approaches to epigenetic modulation by activating HATs and inhibiting HDACs, fundamentally altering the mechanism of action to achieve tumor cell death through transcriptional reprogramming, chromatin remodeling, and restoration of tumor suppressor gene expression, thereby overcoming treatment resistance
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.